サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1798196

ペットがん治療の世界市場

Pet Cancer Therapeutics

出版日
ページ情報
英文 384 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=149.79円
ペットがん治療の世界市場
出版日: 2025年08月26日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 384 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

ペットがん治療の世界市場は2030年までに6億2,460万米ドルに達する見込み

2024年に4億3,090万米ドルと推定されるペットがん治療の世界市場は、分析期間2024～2030年にCAGR 6.4%で成長し、2030年には6億2,460万米ドルに達すると予測されます。本レポートで分析したセグメントの1つである化学療法は、CAGR 6.7％を記録し、分析期間終了時には2億1,840万米ドルに達すると予測されます。放射線療法分野の成長率は、分析期間中CAGR 4.6％と推定されます。

米国市場は1億1,740万米ドルと推定、中国はCAGR10.1％で成長予測

米国のペットがん治療市場は、2024年に1億1,740万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに1億2,860万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは10.1%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.2%と6.2%と予測されています。欧州では、ドイツがCAGR 4.2%で成長すると予測されています。

世界のペットがん治療市場- 主要動向と促進要因まとめ

なぜペットのがん治療が獣医療における優先事項として浮上しているのか？

ペットがん治療は、ペットの寿命の伸び、獣医学的支出の増加、人間の腫瘍学と同様の高度な治療を求める飼い主の傾向の高まりによって、獣医学ヘルスケアにおける最もダイナミックなセグメントの1つに進化しています。がんは高齢の犬や猫の主な死因であり、リンパ腫、肥満細胞腫、骨肉腫、黒色腫、血管肉腫などが流行しています。ペットの飼育が感情的、経済的に深く関わるようになるにつれ、がんと診断されたコンパニオンアニマルの早期発見、効果的な治療、QOLの維持に対する需要が高まっています。

デジタルX線検査、CTスキャン、細針吸引細胞診、免疫組織化学検査が専門クリニックで利用できるようになり、腫瘍の早期同定と分類が可能になったことで、診断法は著しく向上しました。その結果、治療への取り込みが増加しました。獣医腫瘍医は現在、化学療法、標的薬、免疫療法、外科腫瘍学、放射線療法など、より幅広い治療法を利用できます。これらの治療法は、以前は大学付属のセンターに限られていたが、現在では商業的な動物病院チェーンや都市部の診療所にも広がりつつあります。

ペットのための保険、ウェルネス・プラン、ペットに特化した腫瘍学的診断の開発も並行して進んでおり、需要を後押ししています。ペットの飼い主は、治癒目的と緩和ケアの両方の選択肢を提供する治療をますます求めるようになっています。種を超えた臨床試験とバイオマーカーの同定に支えられたヒトと獣医の腫瘍学研究の融合は、技術革新を促進し、獣医市場に合わせたトランスレーショナルな治療を可能にしています。

どのような治療革新が獣医学腫瘍学を再構築しているのか？

ペットがん治療市場で最も注目すべき変化は、一般的な化学療法レジメンから標的療法や免疫療法アプローチへの移行です。モノクローナル抗体（例えば、アラタナ・セラピューティクスのブロントレスやタクトレス）や低分子阻害剤は、特定の腫瘍抗原や増殖経路を標的とし、生存率を向上させ、全身毒性を最小限に抑えるために使用されています。リン酸トセラニブ（パラディア社）などのチロシンキナーゼ阻害剤は現在、犬の肥満細胞腫に日常的に使用されています。

がんワクチンやチェックポイント阻害剤を含む免疫療法は、補助的または単独治療として台頭してきています。犬用メラノーマワクチン（Oncept）は経口メラノーマの犬の生存期間の延長に有望であり、他の自己ワクチンプラットフォームも血管肉腫やリンパ腫を対象に開発中です。遺伝子治療も初期段階から検討されており、ベクターベースの腫瘍抑制遺伝子導入や免疫調節の試験が行われています。

診断の面では、腫瘍の進行や再発をモニターする非侵襲的なツールとして、リキッドバイオプシーや循環腫瘍細胞（CTC）検出が検討されています。AIベースの症状トラッカーや遠隔獣医療相談などのデジタルヘルスツールは、早期のがん症状の特定や治療後のモニタリングに役立っています。このような技術革新は臨床情勢を一変させ、ペットにおけるよりカスタマイズされたデータ主導型のがん管理を可能にしています。

ペット用がん治療薬の普及をリードするセグメントと市場は？

犬は依然として獣医腫瘍学にとって最大の患者集団であり、診断率および治療率は猫よりもかなり高いです。ゴールデン・レトリーバー、ボクサー、バーニーズ・マウンテン・ドッグなどの犬種は特定のがんに対する遺伝的素因を示し、都市部の高所得のペット所有者層に需要が集中しています。猫は診断される頻度は低いもの、猫特有のがん治療薬、特にリンパ腫と扁平上皮がんに対する注目度が高まっています。

市場浸透率が最も高いのは北米、特に米国で、高度な動物病院、腫瘍科専門医、保険診療が広く普及しています。欧州はこれに次いでおり、英国、ドイツ、オランダのような国では、コンパニオンアニマル医薬品に対する認識と規制上の支援により、高い治療導入率が報告されています。アジア太平洋は急成長している地域であり、特に日本、韓国、中国やインドの都市部では、ペットの人間化の動向が専門医療への新たな投資の引き金となっています。

動物病院、ペット病院、診断研究所が主なサプライチェーンを形成しています。化学療法、放射線療法、外科的腫瘍学を提供する専門医療センターが大都市圏で成長しています。また、ペット保険会社は、がん治療、診断、フォローアップ・ケアを含む保険契約を拡大しつつあります。

ペットがん治療世界市場の成長を牽引しているのは？

世界のペットがん治療市場の成長を牽引しているのは、ペットの長寿化、飼い主の高度医療への投資意欲の高まり、診断・治療技術へのアクセスの拡大、獣医学における標的療法と免疫腫瘍学の台頭です。ペットのヒューマニゼーションの動向が深まるにつれて、がん治療は緩和支援から積極的で精密な介入へと移行しつつあります。

ペット保険の利用可能性の拡大、獣医専門医の数の増加、発見率の向上によるがんの有病率の上昇が、治療法の普及を加速させています。動物用医薬品に対する規制上の支援や臨床承認経路の合理化も、新規治療薬の迅速な商業化を可能にしています。トランスレーショナル・リサーチの動向（ヒトの腫瘍学の進歩を活用し、動物用プロトコールに反映させる）は、イノベーションをさらに後押ししています。

ペットの飼育率の上昇、ペットの高齢化、ドラッグデリバリー、腫瘍遺伝学、個別化医療における技術的飛躍に支えられ、腫瘍学は現在、獣医学の専門分野の中核を成しており、ペットがん治療市場は今後も上昇基調を続けると予想されます。

セグメント

療法（化学療法、放射線療法、免疫療法、標的療法、その他の療法）;動物（犬、猫、その他の動物）;用途（リンパ腫用途、肥満細胞がん用途、黒色腫用途、乳腺・扁平上皮がん用途、その他の用途）

調査対象企業の例

  • AB Science
  • Akston Biosciences
  • Anivive Lifesciences
  • Boehringer Ingelheim
  • Dechra Pharmaceuticals
  • Elanco Animal Health
  • ImpriMed
  • Karyopharm Therapeutics
  • LiteCure LLC
  • Mars Petcare
  • Merck Animal Health（MSD）
  • Nippon Zenyaku Kogyo（Zenoaq）
  • Norbrook Laboratories
  • Oasmia Pharmaceuticals
  • PetCure Oncology
  • Pfizer（Zoetis）
  • QBiotics Group Ltd.
  • Regeneus Ltd.
  • SpyBiotech
  • VetDC Inc.

AIインテグレイションズ

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP39184

Global Pet Cancer Therapeutics Market to Reach US$624.6 Million by 2030

The global market for Pet Cancer Therapeutics estimated at US$430.9 Million in the year 2024, is expected to reach US$624.6 Million by 2030, growing at a CAGR of 6.4% over the analysis period 2024-2030. Chemotherapy, one of the segments analyzed in the report, is expected to record a 6.7% CAGR and reach US$218.4 Million by the end of the analysis period. Growth in the Radiation Therapy segment is estimated at 4.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$117.4 Million While China is Forecast to Grow at 10.1% CAGR

The Pet Cancer Therapeutics market in the U.S. is estimated at US$117.4 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$128.6 Million by the year 2030 trailing a CAGR of 10.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.2% and 6.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.2% CAGR.

Global Pet Cancer Therapeutics Market - Key Trends & Drivers Summarized

Why Is Cancer Care in Pets Emerging as a Priority in Veterinary Medicine?

Pet cancer therapeutics is evolving into one of the most dynamic segments in veterinary healthcare, driven by rising pet lifespans, increased veterinary expenditure, and a growing tendency among pet owners to pursue advanced care similar to human oncology. Cancer is the leading cause of death in older dogs and cats, with prevalent forms including lymphoma, mast cell tumors, osteosarcoma, melanoma, and hemangiosarcoma. As pet ownership becomes more emotionally and economically involved, there is a rising demand for early detection, effective treatment, and quality-of-life maintenance in companion animals diagnosed with cancer.

Diagnostics have improved markedly, with the availability of digital radiography, CT scans, fine-needle aspiration cytology, and immunohistochemistry in specialty clinics enabling early-stage identification and classification of tumors. This, in turn, has increased therapeutic uptake. Veterinary oncologists now have access to a wider arsenal of interventions, including chemotherapy, targeted drugs, immunotherapy, surgical oncology, and radiation therapy. These interventions were previously limited to university-affiliated centers but are now expanding into commercial veterinary chains and urban clinics.

Parallel developments in insurance coverage for pets, wellness plans, and pet-focused oncology diagnostics are fueling demand. Pet owners are increasingly seeking treatments that offer both curative intent and palliative care options. The convergence of human and veterinary oncology research, supported by cross-species trials and biomarker identification, is driving innovation and enabling translational therapies tailored to the veterinary market.

What Therapeutic Innovations Are Reshaping Veterinary Oncology?

The most notable shift in the pet cancer therapeutics market is the move from generic chemotherapeutic regimens to targeted and immunotherapeutic approaches. Monoclonal antibodies (e.g., Blontress and Tactress by Aratana Therapeutics) and small-molecule inhibitors are being used to target specific tumor antigens or growth pathways, improving survival and minimizing systemic toxicity. Tyrosine kinase inhibitors such as toceranib phosphate (Palladia) are now routinely used for mast cell tumors in dogs.

Immunotherapies, including cancer vaccines and checkpoint inhibitors, are emerging as adjunctive or standalone treatments. Canine melanoma vaccine (Oncept) has shown promise in extending survival in dogs with oral melanoma, and other autologous vaccine platforms are under development for hemangiosarcoma and lymphoma. Gene therapy is also under early investigation, with trials exploring vector-based tumor suppressor gene delivery and immune modulation.

On the diagnostics side, liquid biopsies and circulating tumor cell (CTC) detection are being explored as non-invasive tools to monitor tumor progression or recurrence. Digital health tools, such as AI-based symptom trackers and tele-veterinary consultations, are helping in early cancer symptom identification and post-treatment monitoring. These innovations are transforming the clinical landscape and enabling more customized, data-driven cancer management in pets.

Which Segments and Markets Are Leading in Pet Oncology Therapeutics Uptake?

Dogs remain the largest patient population for veterinary oncology, with significantly higher diagnosis and treatment rates than cats. Breeds such as Golden Retrievers, Boxers, and Bernese Mountain Dogs show genetic predisposition to certain cancers, leading to demand concentration in urban, high-income pet-owner clusters. Cats, though less frequently diagnosed, are seeing growing attention in feline-specific cancer therapeutics, especially for lymphoma and squamous cell carcinoma.

The highest market penetration exists in North America, particularly the United States, where advanced veterinary hospitals, oncology specialists, and insurance-backed services are widely available. Europe is following closely, with countries like the UK, Germany, and the Netherlands reporting high treatment adoption due to awareness and regulatory support for companion animal drugs. Asia-Pacific is a rapidly growing region, especially in Japan, South Korea, and urban centers in China and India, where pet humanization trends are triggering new investments in specialized care.

Veterinary clinics, pet hospitals, and diagnostic laboratories form the main supply chain. Specialty care centers that offer chemotherapy, radiation, and surgical oncology are growing in metropolitan areas. Pharma companies are increasingly targeting the veterinary oncology space with tailored R&D, while pet insurance providers are broadening coverage policies to include cancer therapies, diagnostics, and follow-up care.

What Is Driving Growth in the Global Pet Cancer Therapeutics Market?

The growth in the global pet cancer therapeutics market is driven by rising pet longevity, increasing willingness among owners to invest in advanced care, growing access to diagnostic and therapeutic technologies, and the emergence of targeted therapies and immuno-oncology in the veterinary sector. As pet humanization trends deepen, cancer treatment is transitioning from palliative support to proactive, precision-based interventions.

Expanding availability of pet insurance, increasing number of veterinary specialists, and rising prevalence of cancer due to better detection are accelerating therapeutic uptake. Regulatory support for veterinary drugs and streamlined clinical approval pathways are also enabling faster commercialization of novel therapies. The trend of translational research-leveraging human oncology advances to inform veterinary protocols-is further supporting innovation.

With oncology now a core pillar of veterinary specialization, the pet cancer therapeutics market is expected to continue its upward trajectory, supported by rising pet adoption rates, aging pet populations, and technological breakthroughs in drug delivery, tumor genetics, and personalized medicine.

SCOPE OF STUDY:

The report analyzes the Pet Cancer Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Therapy (Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies, Other Therapies); Animal (Dog, Cat, Other Animals); Application (Lymphoma Application, Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 39 Featured) -

  • AB Science
  • Akston Biosciences
  • Anivive Lifesciences
  • Boehringer Ingelheim
  • Dechra Pharmaceuticals
  • Elanco Animal Health
  • ImpriMed
  • Karyopharm Therapeutics
  • LiteCure LLC
  • Mars Petcare
  • Merck Animal Health (MSD)
  • Nippon Zenyaku Kogyo (Zenoaq)
  • Norbrook Laboratories
  • Oasmia Pharmaceuticals
  • PetCure Oncology
  • Pfizer (Zoetis)
  • QBiotics Group Ltd.
  • Regeneus Ltd.
  • SpyBiotech
  • VetDC Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Pet Cancer Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Pet Humanization Trends Throw the Spotlight on Advanced Cancer Treatment for Companion Animals
    • Expansion of Veterinary Oncology Services Drives Demand for Novel Cancer Therapeutics in Pets
    • Increased Life Expectancy of Pets Spurs Growth in Age-Related Cancer Diagnoses and Treatments
    • Advancements in Companion Animal Genomics Strengthen Business Case for Targeted Therapeutics
    • Growing Use of Immunotherapies and Monoclonal Antibodies Expands Pet Cancer Treatment Modalities
    • Veterinary Drug Approvals for Canine and Feline Oncology Indications Accelerate Market Maturity
    • Increased Diagnostic Imaging Capabilities in Veterinary Clinics Enhances Cancer Detection Rates
    • Emergence of AI and Digital Pathology Platforms Improves Tumor Identification and Prognosis
    • Growth of Pet Insurance Coverage Supports Affordability and Uptake of Expensive Oncology Therapies
    • Expansion of Veterinary Clinical Trials Network Spurs Innovation in Pet Cancer Drug Development
    • Development of Oral Chemotherapy Formulations Enhances Compliance in At-Home Treatment
    • Increased Focus on Palliative Care and Quality of Life Drives Demand for Adjunctive Oncology Solutions
    • Collaboration Between Human and Veterinary Oncology Research Communities Enables Technology Transfer
    • Rising Demand for Minimally Invasive Treatment Modalities Fuels Adoption of Precision Radiation Systems
    • Pet Owner Awareness Campaigns and Advocacy Groups Drive Early Detection and Therapy Adoption
    • Integration of Companion Diagnostics in Veterinary Oncology Supports Personalized Treatment Plans
    • Expansion of Specialty Veterinary Clinics and Oncology Hospitals Supports Geographic Market Penetration
    • Veterinary Pharmaceutical Investments in Oncology Pipelines Accelerate Product Launches
    • Regulatory Fast-Track Programs for Animal Health Products Support Timely Market Access
    • Evolving Ethical Considerations and Owner Expectations Promote Holistic Pet Cancer Management
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Pet Cancer Therapeutics Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Pet Cancer Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Pet Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Radiation Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Targeted Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Targeted Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Targeted Therapies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Other Therapies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Mast Cell Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Mast Cell Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Mast Cell Cancer Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Melanoma Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Melanoma Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Melanoma Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Mammary & Squamous Cell Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Mammary & Squamous Cell Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Mammary & Squamous Cell Cancer Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Lymphoma Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Lymphoma Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: World 16-Year Perspective for Lymphoma Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Dog by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Dog by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: World 16-Year Perspective for Dog by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Cat by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Cat by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: World 16-Year Perspective for Cat by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for Other Animals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 42: World Historic Review for Other Animals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: World 16-Year Perspective for Other Animals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Pet Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 44: USA Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: USA 16-Year Perspective for Pet Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 47: USA Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: USA 16-Year Perspective for Pet Cancer Therapeutics by Application - Percentage Breakdown of Value Sales for Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application for the Years 2014, 2025 & 2030
    • TABLE 50: USA Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: USA Historic Review for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: USA 16-Year Perspective for Pet Cancer Therapeutics by Animal - Percentage Breakdown of Value Sales for Dog, Cat and Other Animals for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: Canada 16-Year Perspective for Pet Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Canada Historic Review for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: Canada 16-Year Perspective for Pet Cancer Therapeutics by Application - Percentage Breakdown of Value Sales for Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application for the Years 2014, 2025 & 2030
    • TABLE 59: Canada Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Canada Historic Review for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: Canada 16-Year Perspective for Pet Cancer Therapeutics by Animal - Percentage Breakdown of Value Sales for Dog, Cat and Other Animals for the Years 2014, 2025 & 2030
  • JAPAN
    • Pet Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: Japan 16-Year Perspective for Pet Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 65: Japan Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Japan Historic Review for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: Japan 16-Year Perspective for Pet Cancer Therapeutics by Application - Percentage Breakdown of Value Sales for Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application for the Years 2014, 2025 & 2030
    • TABLE 68: Japan Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Japan Historic Review for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: Japan 16-Year Perspective for Pet Cancer Therapeutics by Animal - Percentage Breakdown of Value Sales for Dog, Cat and Other Animals for the Years 2014, 2025 & 2030
  • CHINA
    • Pet Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 71: China Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: China 16-Year Perspective for Pet Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 74: China Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: China Historic Review for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: China 16-Year Perspective for Pet Cancer Therapeutics by Application - Percentage Breakdown of Value Sales for Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application for the Years 2014, 2025 & 2030
    • TABLE 77: China Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: China Historic Review for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: China 16-Year Perspective for Pet Cancer Therapeutics by Animal - Percentage Breakdown of Value Sales for Dog, Cat and Other Animals for the Years 2014, 2025 & 2030
  • EUROPE
    • Pet Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Pet Cancer Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: Europe 16-Year Perspective for Pet Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: Europe 16-Year Perspective for Pet Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 86: Europe Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Europe Historic Review for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: Europe 16-Year Perspective for Pet Cancer Therapeutics by Application - Percentage Breakdown of Value Sales for Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application for the Years 2014, 2025 & 2030
    • TABLE 89: Europe Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Europe Historic Review for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: Europe 16-Year Perspective for Pet Cancer Therapeutics by Animal - Percentage Breakdown of Value Sales for Dog, Cat and Other Animals for the Years 2014, 2025 & 2030
  • FRANCE
    • Pet Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 92: France Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: France 16-Year Perspective for Pet Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 95: France Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: France Historic Review for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: France 16-Year Perspective for Pet Cancer Therapeutics by Application - Percentage Breakdown of Value Sales for Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application for the Years 2014, 2025 & 2030
    • TABLE 98: France Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: France Historic Review for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: France 16-Year Perspective for Pet Cancer Therapeutics by Animal - Percentage Breakdown of Value Sales for Dog, Cat and Other Animals for the Years 2014, 2025 & 2030
  • GERMANY
    • Pet Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Germany 16-Year Perspective for Pet Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 104: Germany Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Germany Historic Review for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: Germany 16-Year Perspective for Pet Cancer Therapeutics by Application - Percentage Breakdown of Value Sales for Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application for the Years 2014, 2025 & 2030
    • TABLE 107: Germany Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Germany Historic Review for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: Germany 16-Year Perspective for Pet Cancer Therapeutics by Animal - Percentage Breakdown of Value Sales for Dog, Cat and Other Animals for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: Italy 16-Year Perspective for Pet Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 113: Italy Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Italy Historic Review for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 115: Italy 16-Year Perspective for Pet Cancer Therapeutics by Application - Percentage Breakdown of Value Sales for Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application for the Years 2014, 2025 & 2030
    • TABLE 116: Italy Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Italy Historic Review for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 118: Italy 16-Year Perspective for Pet Cancer Therapeutics by Animal - Percentage Breakdown of Value Sales for Dog, Cat and Other Animals for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Pet Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 119: UK Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 121: UK 16-Year Perspective for Pet Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 122: UK Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: UK Historic Review for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 124: UK 16-Year Perspective for Pet Cancer Therapeutics by Application - Percentage Breakdown of Value Sales for Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application for the Years 2014, 2025 & 2030
    • TABLE 125: UK Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: UK Historic Review for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 127: UK 16-Year Perspective for Pet Cancer Therapeutics by Animal - Percentage Breakdown of Value Sales for Dog, Cat and Other Animals for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 128: Spain Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Spain Historic Review for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 130: Spain 16-Year Perspective for Pet Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 131: Spain Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Spain Historic Review for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 133: Spain 16-Year Perspective for Pet Cancer Therapeutics by Application - Percentage Breakdown of Value Sales for Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application for the Years 2014, 2025 & 2030
    • TABLE 134: Spain Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Spain Historic Review for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 136: Spain 16-Year Perspective for Pet Cancer Therapeutics by Animal - Percentage Breakdown of Value Sales for Dog, Cat and Other Animals for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 137: Russia Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Russia Historic Review for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 139: Russia 16-Year Perspective for Pet Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 140: Russia Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Russia Historic Review for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 142: Russia 16-Year Perspective for Pet Cancer Therapeutics by Application - Percentage Breakdown of Value Sales for Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application for the Years 2014, 2025 & 2030
    • TABLE 143: Russia Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Russia Historic Review for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 145: Russia 16-Year Perspective for Pet Cancer Therapeutics by Animal - Percentage Breakdown of Value Sales for Dog, Cat and Other Animals for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 148: Rest of Europe 16-Year Perspective for Pet Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Rest of Europe Historic Review for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 151: Rest of Europe 16-Year Perspective for Pet Cancer Therapeutics by Application - Percentage Breakdown of Value Sales for Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application for the Years 2014, 2025 & 2030
    • TABLE 152: Rest of Europe Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Rest of Europe Historic Review for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 154: Rest of Europe 16-Year Perspective for Pet Cancer Therapeutics by Animal - Percentage Breakdown of Value Sales for Dog, Cat and Other Animals for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Pet Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Pet Cancer Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 157: Asia-Pacific 16-Year Perspective for Pet Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 160: Asia-Pacific 16-Year Perspective for Pet Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Asia-Pacific Historic Review for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 163: Asia-Pacific 16-Year Perspective for Pet Cancer Therapeutics by Application - Percentage Breakdown of Value Sales for Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application for the Years 2014, 2025 & 2030
    • TABLE 164: Asia-Pacific Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Asia-Pacific Historic Review for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 166: Asia-Pacific 16-Year Perspective for Pet Cancer Therapeutics by Animal - Percentage Breakdown of Value Sales for Dog, Cat and Other Animals for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Pet Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 167: Australia Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Australia Historic Review for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 169: Australia 16-Year Perspective for Pet Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 170: Australia Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Australia Historic Review for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 172: Australia 16-Year Perspective for Pet Cancer Therapeutics by Application - Percentage Breakdown of Value Sales for Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application for the Years 2014, 2025 & 2030
    • TABLE 173: Australia Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Australia Historic Review for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 175: Australia 16-Year Perspective for Pet Cancer Therapeutics by Animal - Percentage Breakdown of Value Sales for Dog, Cat and Other Animals for the Years 2014, 2025 & 2030
  • INDIA
    • Pet Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 176: India Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: India Historic Review for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 178: India 16-Year Perspective for Pet Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 179: India Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: India Historic Review for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 181: India 16-Year Perspective for Pet Cancer Therapeutics by Application - Percentage Breakdown of Value Sales for Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application for the Years 2014, 2025 & 2030
    • TABLE 182: India Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: India Historic Review for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 184: India 16-Year Perspective for Pet Cancer Therapeutics by Animal - Percentage Breakdown of Value Sales for Dog, Cat and Other Animals for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 185: South Korea Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: South Korea Historic Review for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 187: South Korea 16-Year Perspective for Pet Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 188: South Korea Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: South Korea Historic Review for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 190: South Korea 16-Year Perspective for Pet Cancer Therapeutics by Application - Percentage Breakdown of Value Sales for Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application for the Years 2014, 2025 & 2030
    • TABLE 191: South Korea Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: South Korea Historic Review for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 193: South Korea 16-Year Perspective for Pet Cancer Therapeutics by Animal - Percentage Breakdown of Value Sales for Dog, Cat and Other Animals for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Asia-Pacific Historic Review for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 196: Rest of Asia-Pacific 16-Year Perspective for Pet Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Asia-Pacific Historic Review for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 199: Rest of Asia-Pacific 16-Year Perspective for Pet Cancer Therapeutics by Application - Percentage Breakdown of Value Sales for Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application for the Years 2014, 2025 & 2030
    • TABLE 200: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Asia-Pacific Historic Review for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 202: Rest of Asia-Pacific 16-Year Perspective for Pet Cancer Therapeutics by Animal - Percentage Breakdown of Value Sales for Dog, Cat and Other Animals for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Pet Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Pet Cancer Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 205: Latin America 16-Year Perspective for Pet Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 208: Latin America 16-Year Perspective for Pet Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 209: Latin America Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Latin America Historic Review for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 211: Latin America 16-Year Perspective for Pet Cancer Therapeutics by Application - Percentage Breakdown of Value Sales for Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application for the Years 2014, 2025 & 2030
    • TABLE 212: Latin America Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Latin America Historic Review for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 214: Latin America 16-Year Perspective for Pet Cancer Therapeutics by Animal - Percentage Breakdown of Value Sales for Dog, Cat and Other Animals for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 215: Argentina Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Argentina Historic Review for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 217: Argentina 16-Year Perspective for Pet Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 218: Argentina Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Argentina Historic Review for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 220: Argentina 16-Year Perspective for Pet Cancer Therapeutics by Application - Percentage Breakdown of Value Sales for Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application for the Years 2014, 2025 & 2030
    • TABLE 221: Argentina Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Argentina Historic Review for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 223: Argentina 16-Year Perspective for Pet Cancer Therapeutics by Animal - Percentage Breakdown of Value Sales for Dog, Cat and Other Animals for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 224: Brazil Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Brazil Historic Review for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 226: Brazil 16-Year Perspective for Pet Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 227: Brazil Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Brazil Historic Review for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 229: Brazil 16-Year Perspective for Pet Cancer Therapeutics by Application - Percentage Breakdown of Value Sales for Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application for the Years 2014, 2025 & 2030
    • TABLE 230: Brazil Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Brazil Historic Review for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 232: Brazil 16-Year Perspective for Pet Cancer Therapeutics by Animal - Percentage Breakdown of Value Sales for Dog, Cat and Other Animals for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 233: Mexico Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Mexico Historic Review for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 235: Mexico 16-Year Perspective for Pet Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 236: Mexico Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Mexico Historic Review for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 238: Mexico 16-Year Perspective for Pet Cancer Therapeutics by Application - Percentage Breakdown of Value Sales for Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application for the Years 2014, 2025 & 2030
    • TABLE 239: Mexico Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Mexico Historic Review for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 241: Mexico 16-Year Perspective for Pet Cancer Therapeutics by Animal - Percentage Breakdown of Value Sales for Dog, Cat and Other Animals for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Rest of Latin America Historic Review for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 244: Rest of Latin America 16-Year Perspective for Pet Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Rest of Latin America Historic Review for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 247: Rest of Latin America 16-Year Perspective for Pet Cancer Therapeutics by Application - Percentage Breakdown of Value Sales for Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application for the Years 2014, 2025 & 2030
    • TABLE 248: Rest of Latin America Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Rest of Latin America Historic Review for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 250: Rest of Latin America 16-Year Perspective for Pet Cancer Therapeutics by Animal - Percentage Breakdown of Value Sales for Dog, Cat and Other Animals for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Pet Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Pet Cancer Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 253: Middle East 16-Year Perspective for Pet Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 256: Middle East 16-Year Perspective for Pet Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 257: Middle East Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Middle East Historic Review for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 259: Middle East 16-Year Perspective for Pet Cancer Therapeutics by Application - Percentage Breakdown of Value Sales for Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application for the Years 2014, 2025 & 2030
    • TABLE 260: Middle East Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Middle East Historic Review for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 262: Middle East 16-Year Perspective for Pet Cancer Therapeutics by Animal - Percentage Breakdown of Value Sales for Dog, Cat and Other Animals for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 263: Iran Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Iran Historic Review for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 265: Iran 16-Year Perspective for Pet Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 266: Iran Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Iran Historic Review for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 268: Iran 16-Year Perspective for Pet Cancer Therapeutics by Application - Percentage Breakdown of Value Sales for Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application for the Years 2014, 2025 & 2030
    • TABLE 269: Iran Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Iran Historic Review for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 271: Iran 16-Year Perspective for Pet Cancer Therapeutics by Animal - Percentage Breakdown of Value Sales for Dog, Cat and Other Animals for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 272: Israel Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Israel Historic Review for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 274: Israel 16-Year Perspective for Pet Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 275: Israel Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Israel Historic Review for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 277: Israel 16-Year Perspective for Pet Cancer Therapeutics by Application - Percentage Breakdown of Value Sales for Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application for the Years 2014, 2025 & 2030
    • TABLE 278: Israel Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Israel Historic Review for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 280: Israel 16-Year Perspective for Pet Cancer Therapeutics by Animal - Percentage Breakdown of Value Sales for Dog, Cat and Other Animals for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Saudi Arabia Historic Review for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 283: Saudi Arabia 16-Year Perspective for Pet Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Saudi Arabia Historic Review for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 286: Saudi Arabia 16-Year Perspective for Pet Cancer Therapeutics by Application - Percentage Breakdown of Value Sales for Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application for the Years 2014, 2025 & 2030
    • TABLE 287: Saudi Arabia Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Saudi Arabia Historic Review for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 289: Saudi Arabia 16-Year Perspective for Pet Cancer Therapeutics by Animal - Percentage Breakdown of Value Sales for Dog, Cat and Other Animals for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 290: UAE Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 291: UAE Historic Review for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 292: UAE 16-Year Perspective for Pet Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 293: UAE Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 294: UAE Historic Review for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 295: UAE 16-Year Perspective for Pet Cancer Therapeutics by Application - Percentage Breakdown of Value Sales for Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application for the Years 2014, 2025 & 2030
    • TABLE 296: UAE Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 297: UAE Historic Review for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 298: UAE 16-Year Perspective for Pet Cancer Therapeutics by Animal - Percentage Breakdown of Value Sales for Dog, Cat and Other Animals for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Rest of Middle East Historic Review for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 301: Rest of Middle East 16-Year Perspective for Pet Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Rest of Middle East Historic Review for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 304: Rest of Middle East 16-Year Perspective for Pet Cancer Therapeutics by Application - Percentage Breakdown of Value Sales for Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application for the Years 2014, 2025 & 2030
    • TABLE 305: Rest of Middle East Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Rest of Middle East Historic Review for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 307: Rest of Middle East 16-Year Perspective for Pet Cancer Therapeutics by Animal - Percentage Breakdown of Value Sales for Dog, Cat and Other Animals for the Years 2014, 2025 & 2030
  • AFRICA
    • Pet Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 308: Africa Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Africa Historic Review for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 310: Africa 16-Year Perspective for Pet Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 311: Africa Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Africa Historic Review for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 313: Africa 16-Year Perspective for Pet Cancer Therapeutics by Application - Percentage Breakdown of Value Sales for Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application for the Years 2014, 2025 & 2030
    • TABLE 314: Africa Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 315: Africa Historic Review for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 316: Africa 16-Year Perspective for Pet Cancer Therapeutics by Animal - Percentage Breakdown of Value Sales for Dog, Cat and Other Animals for the Years 2014, 2025 & 2030

IV. COMPETITION